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labelling of the A and the D-form of complex I in SMP. After
reduction-induced chemical proteolysis of surrounding proteins by
Fe(II)-chelate, complex I was isolated and subunits were separated by
2D SDS PAGE. In an additional experiment, in order to label primary
amines accessible in both enzyme molecules we used ﬂuorescent
NHS-esters to identify any conformational difference between the A
and the D-form.
The differential labelling of complex I provided new information
on the structural differences between the two forms of the enzyme.
Physiological consequences of de-activation and possible regulatory
modiﬁcations that target one of the forms physiologically are
discussed.
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NADH-ubiquinone oxidoreductase (complex I) is the ﬁrst and the
largest enzyme in the respiratory chain of mitochondria and most
bacteria. Complex I catalyses the transfer of two electrons from NADH
to quinone, coupled to the translocation of about four protons across
the membrane. The mitochondrial enzyme contains 45 different
subunits, while the bacterial enzyme consists of 13–15 different
subunits. Analogues of all conserved bacterial subunits are found in
the mitochondrial enzyme. We study bacterial complex I as a
“minimal” model of the mitochondrial enzyme. It is an L-shaped
assembly, with the hydrophobic arm embedded in the membrane and
the hydrophilic arm protruding into the bacterial cytoplasm.
Recently, we have crystallised the entire complex I from Thermus
thermophilus and determined its architecture by molecular replace-
ment with the structures of the hydrophilic and the hydrophobic
domains [1]. We have now identiﬁed a novel T. thermophilus protein
of about 14.2 kDa, which is not part of the nqo operon. This protein is
present in approximately 50% of the total puriﬁed complex I,
depending on the cell growth and conditions. It does not appear to
be necessary for activity, including proton-pumping. However, it is
essential for crystallisation of the intact complex — it is involved in
crystal contacts, and may also stabilise the junction between the two
main domains, as it binds to the hydrophilic arm close to the
hydrophobic domain. Although there are many chaperones/assembly
factors known for the mitochondrial complex I, this is the ﬁrst case of
a chaperone-like protein described for bacterial complex I.
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Type II or alternative NADH dehydrogenases (NDH-II) are
monomeric enzymes with a molecular mass of ≈50 kDa containing
FAD as the only prosthetic group. They are membrane associated
proteins that catalyse NADH:quinone oxidoreduction but do not
directly contribute to the establishment of the membrane potential.
NDHs-II are present in the three domains of life. In eukaryotes,
their presence has been observed in plants, fungi and protozoa. In
several organisms, especially in pathogenic such as Staphylococcus
aureus, only NDH-II is expressed, which raises the possibility for
rational design of speciﬁc drugs interacting at the level of this
enzyme, which is not present in animal mitochondria. Furthermore,
NDHs-II have been suggested to be used in gene therapy correcting
NADH:quinone oxidoreductase activity in pathologies with
malfunctioning complex I such as neurodegenerative disorders. Thus,
not only for its importance in bioenergetics, but also in other areas
such as health a deep knowledge of NDH-II is demanded.
Although being a simple enzyme and having been isolated for the
ﬁrst time more than thirty years ago, fundamental questions
regarding its structural/functional relation are still unanswered. Its
structure, the substrate binding sites, and its membrane association
mode are still unknown. Also its functional mechanism has to be
investigated, namely concerning the interaction with the substrates
and the way FAD is reduced by NADH and oxidised by the quinone.
In this work conformational changes in NDH-II from Escherichia
coli due to interactions with its substrates (NADH and quinone) were
monitored. For that, changes in the ﬂuorescence of tryptophan
residues in response to ligand binding were followed. In order to
identify the structural elements/motifs involved in substrate interac-
tion, surface enhanced infrared absorption (SEIRA) spectroscopy was
applied.
It was observed that the protein reacts with NADH and with
different quinones promoting the interaction of the ubiquinone
analogue, apparently, more pronounce conformational changes. The
involvement of Trp and Glu/Asn residues in the binding of NADH and
ubiquinone is suggested. The obtained results prompt us to extend
the project to the study of NDHs-II from organisms that synthesize
different quinones. A comparative study showing the differences
between ubiquinone and menaquinone bindings will be showed.
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Mitochondrial Complex I (NADH ubiquinone oxidoreductase) is
the ﬁrst of three energy transducing enzymes of the respiratory chain.
Loss of Complex I activity is associated with ageing, neu-
rodegeneration and ischaemia–reperfusion injury rendering further
investigation of Complex I catalytic regulation pertinent.
The mammalian enzyme can exist in two conformationally-
distinct, interconvertible forms — active (A) and dormant, de-active
(D). These forms have been described in intact cells [1] and recently
in various tissues in ischaemia (as further described in [2] of this
issue). The high activation energy of 270 kJ/mol of the A to D
transition [3] indicates the occurrence of major conformational
changes in Complex I.
In this work we have developed an approach to analyse the
differences in relative location of Complex I subunits in the A and the
D-form. Using preparation of bovine heart submitochondrial particles
(SMP), we have established the conditions in which the majority of
the enzyme is present in the D-form or, alternatively, the majority is
in the A-form. Several hetero- and homobifunctional crosslinkers of
different length were used. Complex I was isolated using Blue Native
electrophoresis and subunits were separated using 2D SDS PAGE. The
crosslinking products were analysed by MS/MS and based on the
presented data possible differences in the relative location of
Complex I subunits are discussed.
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Complex I catalyses the two electron oxidation of NADH by
quinone, to drive proton pumping across an energy transducing
membrane. Much work on complex I has been done using sub-
mitochondrial particles derived from the inner membrane of
mitochondria, these have the active sites of the respiratory complexes
facing the bulk solution to allow the direct access of substrates. An
analogous system can be created using Paracoccus denitriﬁcans, based
on osmotic rupture of lysozyme digested cells. P. denitriﬁcans is an
ideal model for mammalian complex I as all the subunits can be
mutated via genomic manipulation; additionally, P. denitriﬁcans
complex I is closely related to the eukaryotic enzyme. Monitoring
NADH at 340 nm is easy, but monitoring proton pumping is much
harder; available methods are either only semi-quantitative or have a
response time that is too slow to follow the pre-steady state reactions
that build the proton motive force. We have developed a robust
system that allows small changes in pH in the bulk solution outside of
the vesicles to be monitored by using pH probes. Our system allows
NADH oxidation and proton translocation to be monitored alongside
each other; we aim to use changes in these activities induced by
mutagenesis to construct a quantitative model of complex I catalysis.
doi:10.1016/j.bbabio.2012.06.147
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Metformin is widely prescribed for the management of type 2
diabetes. It has been proposed to exert its beneﬁcial effects by
inhibiting respiratory complex I in mitochondria; the inhibition has
been proposed to activate AMP kinase, triggering a cascade which
increases glucose uptake, inhibits gluconeogenesis and fatty acid
synthesis in the liver, and regulates insulin synthesis and secretion in
pancreatic islet cells [1,2]. More recently, metformin treatment has
been linked to anticancer beneﬁts [3]. Therefore, it is crucial to
determine precisely how this drug produces its observed effects.
Complex I has been proposed as the primary target of metformin
due to the observed decrease in NADH-linked oxygen consumption in
intact cells, isolated mitochondria and submitochondrial particles
upon metformin treatment [1,4]. However, the molecular mechanism
of inhibition has not yet been deduced. In this work, the effects of
metformin on catalysis by isolated bovine complex I are described
on a molecular level, and the projected impacts and downstream
effects of the inhibition caused by therapeutically-relevant levels are
discussed.
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Mitochondrial complex I catalyses electron transfer from NADH to
ubiquinone and it is the major entry point of substrates to the
respiratory chain. Complex I not only produces O–2 through the auto-
oxidation of ﬂavin-semiquinone, but also it is sensitive to oxidants
and reactive nitrogen species. NO inhibits complex I activity by S-
nitrosylation or Fe-nitrosation. Mitochondrial NO production is
carried out by the mtNOS, a NOS located in mitochondrial inner
membrane. Persichini et al. [1] reported that mtNOS is associated to
Va subunit of cytochrome oxidase. Franco et al. [2] showed that not
only complex IV but also complex I proteins immunoprecipitate with
mtNOS, suggesting direct physical interactions between mtNOS and
complexes I and IV proteins. Therefore, the aim of this work was to
characterize the functional interaction between complex I andmtNOS
using phosphorylating electron transfer particles (ETPH-Mg2+), i.e.
inside-out vesicles, that expose NADH dehydrogenase and mtNOS to
the surrounding medium. ETPH-Mg2+ showed a NAD+ reductase
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